Critical Roles of ELVOL4 and IL-33 in the Progression of Obesity-Related Cardiomyopathy via Integrated Bioinformatics

Jun Tao1, Yajing Wang2, Ling Li1

  • 1Department of Cardiovascular Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.

Insights

This study identifies ELOVL4 and IL-33 as potential biomarkers for obesity-related cardiomyopathy (ORCM). These genes, found through bioinformatics analysis, may offer new diagnostic and therapeutic targets for ORCM patients.

Area of Science:

  • Cardiovascular Research
  • Genomics and Bioinformatics
  • Metabolic Diseases

Background:

  • Obesity-related cardiomyopathy (ORCM) lacks effective pharmacological treatments due to complex molecular mechanisms.
  • Identifying novel therapeutic targets and diagnostic biomarkers for ORCM is crucial for patient outcomes.
  • Bioinformatics approaches, particularly gene expression profiling, offer powerful tools for discovering disease-related genes.

Purpose of the Study:

  • To identify potential genes and molecular targets associated with obesity-related cardiomyopathy (ORCM) using integrated bioinformatics analysis.
  • To explore novel diagnostic biomarkers and therapeutic strategies for ORCM.
  • To validate the expression levels of identified hub genes in clinical samples.

Main Methods:

  • Utilized microarray datasets (GSE18897 and GSE47022) for gene expression profiling.
  • Applied Weighted Gene Co-expression Network Analysis (WGCNA) to identify gene modules correlated with clinical phenotypes.
  • Performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses.
  • Validated hub gene expression in clinical peripheral blood samples.

Main Results:

  • The WGCNA identified a 'yellow module' significantly associated with caloric restriction, linked to oxygen transport and porphyrin pathways.
  • Overlap analysis revealed six upregulated genes common to both human and mouse datasets.
  • Experimental validation confirmed upregulation of ELOVL4, MMP-8, and IL-33 in ORCM patients.
  • ELOVL4 expression positively correlated with IL-33 expression.

Conclusions:

  • ELOVL4 and IL-33 emerge as potential biomarkers for the diagnosis and/or treatment of obesity-related cardiomyopathy (ORCM).
  • These identified hub genes warrant further investigation into their specific roles in ORCM pathophysiology.
  • Integrated bioinformatics analysis, including WGCNA, is effective for discovering novel therapeutic targets in complex diseases like ORCM.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
261
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
336
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
317